the findings could be used to inform the committee on BI-RADS regarding the possible incorporation of the MBI lexicon into the BI-RADS Atlas

A, Mass (arrow) with marked intensity of uptake. B, Nonmass uptake (arrow) with focal distribution and mild intensity of uptake. C, Nonmass uptake (arrow) with segmental distribution and moderate intensity of uptake. D, Nonmass uptake (arrow) with regional distribution and mild intensity of uptake. E, Nonmass uptake (arrow) with diffuse distribution and marked intensity of uptake. 


July 21, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), understanding the likelihood of malignancy associated with the molecular breast imaging (MBI) lexicon’s lesion descriptors can help guide interpretations. 

Acknowledging further research is needed to determine the optimal application of a probably benign assessment for positive MBI findings, “PPV was higher for masses, lesions seen on multiple MBI views, and lesions with marked uptake intensity,” wrote lead author Katie N. Hunt, MD, from the radiology department at Mayo Clinic in Rochester, MN. 

Dr. Hunt and team’s retrospective study included positive MBI examinations—BI-RADS analogous categories 0, 3, 4, or 5—performed from August 1, 2005, through August 31, 2017, using dual-detector, cadmium zinc telluride MBI systems after radiotracer injection (technetium 99m sestamibi). Two radiologists analyzed 643 lesions in 509 patients (median age, 56 years) based on lexical type (mass vs. nonmass uptake), distribution (if nonmass uptake), uptake intensity, and number of views wherein the lesion was observed. 

Ultimately, PPV for malignancy was 73.5% for mass and 18.4% for nonmass uptake; among nonmass uptake, PPV was highest for those with segmental distribution (36.8%). PPV was 14.0% for mild, 22.4% for moderate, and 64.8% for marked intensity of uptake. 

“As MBI continues to be integrated into breast imaging practices,” the authors of this AJR article concluded, “the findings could be used to inform the committee on BI-RADS regarding the possible incorporation of the MBI lexicon into the BI-RADS Atlas.” 

For more information: arrs.org 


Related Content

News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Breast Imaging

June 20, 2024 — The technologically advanced VELA Mammography Chair, offered by Enable Me, a VELA Medical company ...

Time June 20, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | Breast Imaging

June 18, 2024 — Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue Breast ...

Time June 18, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiology Business

June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...

Time June 12, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
News | PET Imaging

June 11, 2024 — A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never ...

Time June 11, 2024
arrow
Subscribe Now